Watching Aardvark Therapeutics, Inc.? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planAardvark Therapeutics, Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Aardvark Therapeutics remains a pre-revenue clinical-stage biopharmaceutical company entirely dependent on its lead candidate ARD-101 for Prader-Willi Syndrome. Six-month net loss grew 52% year-over-year to $36.0 million, driving a nearly 30% decline in total assets and stockholders' equity since year-end 2025, as cash and short-term investments were consumed to fund R&D and rapidly rising G&A expenses. Absent additional financing, the current cash burn rate suggests roughly 12 months or less of operating runway, reinforcing the company's stated need for substantial additional capital.
Red Flags Detected (8)
Accumulated deficit increased from $115.9M to $151.9M in just six months, a 31% jump
Six-month net loss rose 52% YoY ($35.975M vs $23.677M), despite flat quarterly loss
Total stockholders' equity fell nearly 30% (from $106.6M to $74.8M) in two quarters
5 more red flags detected
Key Takeaways
Company has no approved products and remains fully reliant on regulatory success of ARD-101
Cash position of $73.8M plus minimal short-term investments provides limited runway at current burn rates (~$18M/quarter operating loss)
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.